Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Oct;38(10):2296–2299. doi: 10.1128/aac.38.10.2296

In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia.

Y Niki 1, M Kimura 1, N Miyashita 1, R Soejima 1
PMCID: PMC284733  PMID: 7840560

Abstract

The in vitro and in vivo activities of azithromycin against chlamydia were investigated. The MIC of azithromycin for five standard strains of different species of chlamydia and six wild-type strains of Chlamydia pneumoniae was 0.125 microgram/ml, which was superior to that of erythromycin but inferior to those of clarithromycin and minocycline. However, the therapeutic effect of a 7-day course of azithromycin at a dose of 10 mg/kg of body weight administered orally once daily to mice with experimental Chlamydia psittaci pneumonia was excellent, with a 100% survival rate at 14 days after infection, which was the same as that for treatment with minocycline administered at 10 mg/kg twice daily; all erythromycin treated animals died within 10 days. When treatment was discontinued 3 days after the infection, the survival rate for mice treated with azithromycin was 90% and that for mice administered minocycline was 30%. These results suggest that azithromycin may be useful in the treatment of respiratory infections caused by intracellular pathogens, including chlamydia because of its excellent accumulation within host cells.

Full text

PDF
2296

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agacfidan A., Moncada J., Schachter J. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 1993 Sep;37(9):1746–1748. doi: 10.1128/aac.37.9.1746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bruaire J. P., Ducroix J. P., Eb F., Smail A., Cohen G., Orfila J., Baillet J. Pneumopathies à Chlamydia pneumoniae. Presse Med. 1992 Jun 20;21(23):1064–1069. [PubMed] [Google Scholar]
  3. Coates P., Daniel R., Houston A. C., Antrobus J. H., Taylor T. An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers. Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):850–852. doi: 10.1007/BF01975839. [DOI] [PubMed] [Google Scholar]
  4. Edelstein P. H., Edelstein M. A. In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrob Agents Chemother. 1991 Jan;35(1):180–181. doi: 10.1128/aac.35.1.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fenelon L. E., Mumtaz G., Ridgway G. L. The in-vitro antibiotic susceptibility of Chlamydia pneumoniae. J Antimicrob Chemother. 1990 Dec;26(6):763–767. doi: 10.1093/jac/26.6.763. [DOI] [PubMed] [Google Scholar]
  6. Foulds G., Shepard R. M., Johnson R. B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):73–82. doi: 10.1093/jac/25.suppl_a.73. [DOI] [PubMed] [Google Scholar]
  7. Gladue R. P., Bright G. M., Isaacson R. E., Newborg M. F. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother. 1989 Mar;33(3):277–282. doi: 10.1128/aac.33.3.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Grayston J. T., Wang S. P., Kuo C. C., Campbell L. A. Current knowledge on Chlamydia pneumoniae, strain TWAR, an important cause of pneumonia and other acute respiratory diseases. Eur J Clin Microbiol Infect Dis. 1989 Mar;8(3):191–202. doi: 10.1007/BF01965260. [DOI] [PubMed] [Google Scholar]
  9. Hammerschlag M. R., Qumei K. K., Roblin P. M. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Jul;36(7):1573–1574. doi: 10.1128/aac.36.7.1573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hardy D. J., Hensey D. M., Beyer J. M., Vojtko C., McDonald E. J., Fernandes P. B. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother. 1988 Nov;32(11):1710–1719. doi: 10.1128/aac.32.11.1710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kimura M., Kishimoto T., Niki Y., Soejima R. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. Antimicrob Agents Chemother. 1993 Apr;37(4):801–803. doi: 10.1128/aac.37.4.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kinasewitz G., Wood R. G. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):872–877. doi: 10.1007/BF01975846. [DOI] [PubMed] [Google Scholar]
  13. Lode H. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):807–812. doi: 10.1007/BF01975832. [DOI] [PubMed] [Google Scholar]
  14. McDonald P. J., Pruul H. Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):828–833. doi: 10.1007/BF01975835. [DOI] [PubMed] [Google Scholar]
  15. Retsema J., Girard A., Schelkly W., Manousos M., Anderson M., Bright G., Borovoy R., Brennan L., Mason R. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother. 1987 Dec;31(12):1939–1947. doi: 10.1128/aac.31.12.1939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ridgway G. L., Mumtaz G., Fenelon L. The in-vitro activity of clarithromycin and other macrolides against the type strain of Chlamydia pneumoniae (TWAR). J Antimicrob Chemother. 1991 Feb;27 (Suppl A):43–45. doi: 10.1093/jac/27.suppl_a.43. [DOI] [PubMed] [Google Scholar]
  17. Schönwald S., Skerk V., Petricevic I., Car V., Majerus-Misic L., Gunjaca M. Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):877–880. doi: 10.1007/BF01975847. [DOI] [PubMed] [Google Scholar]
  18. Slaney L., Chubb H., Ronald A., Brunham R. In-vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):1–5. doi: 10.1093/jac/25.suppl_a.1. [DOI] [PubMed] [Google Scholar]
  19. Welsh L. E., Gaydos C. A., Quinn T. C. In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Feb;36(2):291–294. doi: 10.1128/aac.36.2.291. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES